SCHEMBL1005445

SCHEMBL1005445

Cc1ccccc1N1[C]N(c2ccccc2C)C=C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
MGLL Q99685 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 3/20 0.41
ACHE P22303 2/20 0.41
ADRB1 P08588 1/20 0.41
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 3/20 0.39
ELANE P08246 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
ALOX5 P09917 1/20 0.36
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14658329 1.00 ALDH1A1 (0.43) ALDH1A1MGLLHPGDSMN1; SMN2TSHR
SCHEMBL1155762 0.73 CYP2A6 (0.38) ALDH1A1TSHRACHEMEN1KMT2A
SCHEMBL1005413 0.70 ADRB1 (0.48) ALDH1A1MGLLHPGDSMN1; SMN2TSHR
SCHEMBL10983420 0.69 MGLL (0.62) ALDH1A1MGLLHPGDSMN1; SMN2TSHR
SCHEMBL6678527 0.68 POLB (0.46) ALDH1A1HPGDTSHRMEN1KMT2A
SCHEMBL22430823 0.67 ALDH1A1 (0.43) ALDH1A1MGLLHPGDSMN1; SMN2TSHR
SCHEMBL1156328 0.67 ALDH1A1 (0.48) ALDH1A1MGLLHPGDSMN1; SMN2TSHR
Hydrochloric Acid SCHEMBL1155766 0.65 ALDH1A1 (0.47) ALDH1A1MGLLHPGDSMN1; SMN2TSHR
SCHEMBL19725777 0.65 ALDH1A1 (0.42) ALDH1A1MGLLHPGDSMN1; SMN2TSHR
SCHEMBL1126941 0.65 CYP1A2 (0.61) ALDH1A1MGLLHPGDSMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2826802-B1 METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION ZEON CORP (JP) 2021-03-10 EP disclosed
US-20180127520-A1 METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION ZEON CORPORATION (JP) 2018-05-10 US disclosed
EP-2739653-B1 METHODS OF POLYMERIZING SILANES AND CYCLOSILANES USING N-HETEROCYCLIC CARBENES AND METAL COMPLEXES HAVING N-HETEROCYCLIC CARBENE LIGANDS THIN FILM ELECTRONICS ASA (NO) 2018-01-10 EP disclosed
US-9850325-B2 Method for producing ring-opening metathesis polymer hydride, and resin composition ZEON CORPORATION (JP) 2017-12-26 US disclosed
EP-1534722-B1 RHODIUM AND IRIDIUM COMPLEXES MERCK PATENT GMBH (DE) 2017-03-22 EP disclosed
EP-2270063-B1 PROCESS FOR PRODUCING HYDROGENATED PRODUCT OF CYCLIC OLEFIN POLYMER PREPARED THROUGH RING-OPENING POLYMERIZATION ZEON CORP (JP) 2016-03-23 EP disclosed
US-20150051353-A1 METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION ZEON CORPORATION (JP) 2015-02-19 US disclosed
EP-2826802-A1 METHOD FOR PRODUCING RING-OPENING METATHESIS POLYMER HYDRIDE, AND RESIN COMPOSITION Zeon Corporation (JP) 2015-01-21 EP disclosed
US-8900654-B2 Methods of polymerizing silanes and cyclosilanes using N-heterocyclic carbenes, metal complexes having N-heterocyclic carbene ligands, and lanthanide compounds Thin Film Electronics, Inc. (NO) 2014-12-02 US disclosed
EP-2289902-B1 Rhodium and iridium complexes MERCK PATENT GMBH (DE) 2014-04-30 EP disclosed
EP-1275675-B1 COPOLYMER FORMED BY RING-OPENING POLYMERIZATION, PRODUCT OF HYDROGENATION OF COPOLYMER FORMED BY RING-OPENING POLYMERIZATION, AND PROCESSES FOR PRODUCING THESE ZEON CORP (JP) 2005-12-07 EP disclosed
US-6908970-B2 Process for producing hydrogenated product of cyclic olefin polymer prepared through ring-opening polymerization ZEON CORPORATION (JP) 2005-06-21 US disclosed
EP-1379534-B1 RHODIUM AND IRIDIUM COMPLEXES COVION ORGANIC SEMICONDUCTORS (DE) 2004-12-15 EP disclosed
US-6815516-B2 HEAT RESISTANCE, SOLVENT SOLUBILITY ZEON CORPORATION (JP) 2004-11-09 US disclosed
US-20040133004-A1 Rhodium and iridium complexes MERCK PATENT GMBH (DE) 2004-07-08 US disclosed
US-20030050406-A1 Process for producing hydrogenated product of cyclic olefin polymer prepared through ring-opening polymerization ZEON CORPORATION 2003-03-13 US disclosed
US-20030018138-A1 Copolymer formed by ring -opening polymerization, product of hydrogenation of copolymer formed by ring-opening polymerization, and process for producing these ZEON CORPORATION (JP) 2003-01-23 US disclosed
EP-1275675-A1 COPOLYMER FORMED BY RING-OPENING POLYMERIZATION, PRODUCT OF HYDROGENATION OF COPOLYMER FORMED BY RING-OPENING POLYMERIZATION, AND PROCESSES FOR PRODUCING THESE Zeon Corporation (JP) 2003-01-15 EP disclosed
US-6486264-B1 Process for producing hydrogenated ring-opening polymerization polymer of cycloolefin ZEON CORPORATION (JP) 2002-11-26 US disclosed
EP-1197509-A1 PROCESS FOR PRODUCING HYDROGENATED RING-OPENING POLYMERIZATION POLYMER OF CYCLOOLEFIN Nippon Zeon Co., Ltd. (JP) 2002-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133004-A1 Rhodium and iridium complexes RPIA, SIRT5, INPP5B ALDH1A1 1115/4885MGLL 3290/4885HPGD 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.